Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others),

Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Antiviral drugs are prescription medicine such as pills, liquid, or intravenous solution to treat HIV, hepatitis B and C viruses, influenza A and B viruses, and herpes viruses. Antiviral drugs are different from antibiotics, which fight against bacterial infections.
Furthermore, the global antiviral drugs market is driven by increasing prevalence of viral infection such as HIV/AIDS. For instance, according to the report of Joint United Nations Programme (UNAIDS) (2021), there were 37.9 million people suffering from HIV/AIDS and around 770,000 people died from this disease globally in 2021.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global antiviral drugs market.
For instance, in April 2021, Zydus Cadila, a pharmaceutical company has received Drug Controller General of India (DCGI) approval for its antiviral drug Virafin for the treatment of moderate COVID-19 infection in adults.
Key features of the study:
This report provides in-depth analysis of the global antiviral drugs market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiviral drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GlaxoSmithKline plc, AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antiviral drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiviral drugs market
Detailed Segmentation:
Global Antiviral Drugs Market, By Drug Class:
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
Global Antiviral Drugs Market, By Type:
Branded
Generics
Global Antiviral Drugs Market, By Application:
HIV
Hepatitis
Herpes
Influenza
Others
Global Antiviral Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Antiviral Drugs Market, By Region:
North America
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
GlaxoSmithKline plc *
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
AbbVie Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Cipla Inc.
Aurobindo Pharma
Gilead Sciences
“*” marked represents similar segmentation in other categories in the respective section.